Skip to content

Multi-Centre European Photopatch Test Study

A Prospective, Open, Multi-Centre Photopatch Test Study of Patients Suspected of Photoallergy to Organic Sunscreens and Topical Nonsteroidal Anti-inflammatory Drugs Used Within Europe.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00530387
Enrollment
1000
Registered
2007-09-17
Start date
2008-07-31
Completion date
2011-07-31
Last updated
2011-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatitis, Photocontact

Keywords

Photocontact, Dermatitis, NSAID, Sunscreen, Photopatch

Brief summary

It is known that people can develop an allergic skin reaction to a substance which is placed on the skin and then subjected to sunlight. This process is called Photocontact allergic dermatitis. It is known that people can develop Photocontact allergic dermatitis to sunscreen chemicals (filters) and also cream forms of pain-killing drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). The purpose of this study is to determine the frequency of Photocontact allergic dermatitis to 19 sunscreen filters and 5 topical NSAIDs in 1,000 European patients who present to a dermatologist with a sun-exposed site dermatitis. Each participant will have the 24 test agents plus one control of petrolatum applied to the skin of the back for 24 or 48 hours. After removal of the substances, the area of skin will be exposed to a precise amount of ultraviolet-A light. The area is then assessed 24, 48 and 72 hours later to see if a photocontact allergic reaction has occured. This method is known as photopatch testing. The study will run for one year, during which time it is planned to recruit 1,000 patients.

Detailed description

Specific Intervention Names: * Butyl-methoxy-dibenzoylmethane * Homosalate * Methylbenzylidene camphor * Benzophenone-3 * Octyl methoxycinnamate * Phenylbenzimidazol sulfonic acid * Benzophenone 4 * Drometrizole trisiloxane * Octocrylene * Octyl salicylate * Octyl triazone * Isoamyl-p-methoxycinnamate * Terephtalidene dicamphor sulphonic acid (Mexoryl SX) * Tinosorb S * Tinosorb M * Univul A+ * Neoheliopan AP * Uvasorb HEB * Parsol SLX * Ketoprofen 1% * Etofenamate 2% * Piroxicam 1% * Diclofenac 5% * Ibuprofen 5 %

Interventions

DRUG19 organic sunscreen filters and 5 topical NSAIDs

Sponsors

NHS Tayside
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female aged 18 years or older. * Have sufficient cognitive capacity to give written informed consent. * Have an eruption on photo-exposed sites, which is to be further classified using one (or more) of the categories below: * Known photosensitivity disease * History of sunscreen reaction * Sun exposed site dermatitis during summer months * Any sun exposed site dermatitis problem

Exclusion criteria

* Male or female aged 17 years or younger * Have had potent topical steroid applied to the photopatch test site on the back in the previous 5 days. (This potentially suppresses reactions which would otherwise have been visible) * Have skin disease on the back which is too active to allow testing. (This obscures the sites of testing by making differentiation between a positive result and other skin disease difficult) * Be prescribed systemic immunosuppressant medication (e.g. prednisolone, methotrexate, azathioprine, ciclosporin) (This potentially suppresses reactions which would otherwise have been visible) * Be taking any photoactive medicine (for example thiazides, sulphonamide derivatives, amiodarone, fluoroquinolones, chlorpromazine, NSAIDs, quinine). (This is a relative exclusion. Many centres may wish to go ahead despite such medication).

Design outcomes

Primary

MeasureTime frame
The development of a photocontact allergic skin response to sunscreen filters and topical NSAIDs, as graded by the ICDRG scale.Within 72 hours of irradiation of patch test site

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026